News | January 13, 2025
Apotex acquires US rights to PROVIGIL and NUVIGIL
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Subscribe To Our Newsletter & Stay Updated
